Singapore: ProMetic Life Sciences has finalized the $10 million strategic equity investment by Shenzhen Hepalink Pharmaceutical pursuant to the terms and conditions previously disclosed on October 16, 2012.

Mr Pierre Laurin, president and CEO, ProMetic, said that, "The funds received will enable the execution of various strategic initiatives, including the 2013 operational launch of ProMetic's GMP plasma facility, located in Laval, Quebec in Canada, and dedicated to the manufacturing of plasma derived products."